TrackedBio (TRACKEDBIO)

TrackedBio (TRACKEDBIO) is committed to transforming the biomedical research and drug discovery landscape through its innovative and advanced high-throughput phenotyping system. This cutting-edge platform integrates artificial intelligence and computer vision technologies, enabling rapid and precise analysis of extensive phenotyping data. As a result, researchers in both animal models and human studies can significantly accelerate their discovery processes, leading to more efficient research outcomes.

A central goal of TrackedBio is to enhance the translation of drug development from preclinical studies to clinical trials. By employing accurate models that simulate the effects of potential drugs on diverse organisms and humans, the platform seeks to streamline the entire drug development cycle. This approach not only aims to reduce the associated costs and time-to-market but also strives to improve the probability of favorable clinical results, making substantial contributions to the pharmaceutical industry.

Dedicating to making a profound societal impact, TrackedBio focuses on providing a transformative platform that advances the understanding of life sciences and facilitates the development of cutting-edge drugs for human health. The company prides itself on its diverse background, being a woman- and minority-owned small business. The team’s robust experience in research and information technology supports the delivery of innovative solutions, leveraging state-of-the-art advancements in artificial intelligence, computer vision automation, and enhanced statistical algorithms.